New test could tailor chemo for bile duct cancer patients after surgery
NCT ID NCT07156058
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a quick lab test called MiniPDX can help doctors choose the best chemotherapy drugs for people with bile duct cancer after surgery. The test measures how sensitive a patient's tumor cells are to different drugs in just 7 days. Researchers will follow 204 participants to see if this personalized approach improves how long they stay cancer-free compared to standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine, gemcitabine, cisplatin, oxaliplatin, 5-FU
What this could lead to
If successful, this could show that using a rapid drug sensitivity test helps choose more effective chemotherapy after surgery, potentially delaying cancer return.
What could go wrong
This is an early-stage, non-randomized study with no control group, so results may not prove the test improves outcomes. The test itself may not accurately predict drug response in all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact